Treace Appoints Guy Guglielmino as Chief Commercial Officer
Treace Medical Concepts (NasdaqGS: TMCI), a medical technology company specializing in surgical treatments for bunions and midfoot deformities through its Lapiplasty® and Adductoplasty® Procedures, has appointed Guy Guglielmino as Chief Commercial Officer. In this new role, Guglielmino will lead the company's commercial efforts and drive innovation, product commercialization, and growth. He joins Treace with extensive medical technology industry experience, most recently serving as President, Recovery Sciences at Enovis, with previous senior Marketing roles at Wright Medical and Bausch + Lomb.
Treace Medical Concepts (NasdaqGS: TMCI), una compagnia di tecnologia medica specializzata nei trattamenti chirurgici per alluce valgo e deformità del mesopiede tramite le procedure Lapiplasty® e Adductoplasty®, ha nominato Guy Guglielmino come Chief Commercial Officer. In questo nuovo ruolo, Guglielmino guiderà gli sforzi commerciali dell'azienda e promuoverà innovazione, commercializzazione dei prodotti e crescita. Si unisce a Treace con un'ampia esperienza nell'industria della tecnologia medica, avendo recentemente ricoperto il ruolo di Presidente, Recovery Sciences presso Enovis, con precedenti posizioni di marketing senior in Wright Medical e Bausch + Lomb.
Treace Medical Concepts (NasdaqGS: TMCI), una empresa de tecnología médica especializada en tratamientos quirúrgicos para juanetes y deformidades del mediopie a través de sus procedimientos Lapiplasty® y Adductoplasty®, ha nombrado a Guy Guglielmino como Director Comercial. En este nuevo puesto, Guglielmino liderará los esfuerzos comerciales de la empresa y fomentará la innovación, la comercialización de productos y el crecimiento. Se une a Treace con una amplia experiencia en la industria de tecnología médica, habiendo sido Presidenta de Recovery Sciences en Enovis y con roles previos de marketing senior en Wright Medical y Bausch + Lomb.
Treace Medical Concepts (NasdaqGS: TMCI)는 Lapiplasty® 및 Adductoplasty® 절차를 통해 엄지발가락과 중족 붕괴에 대한 수술적 치료를 전문으로 하는 의료 기술 회사로, Guy Guglielmino을 최고 상업 책임자(Chief Commercial Officer)로 임명했습니다. 이 새로운 역할에서 Guglielmino는 회사의 상업적 노력을 이끌고 혁신, 제품 상용화 및 성장을 추진할 것입니다. 그는 Enovis의 회복 과학 부사장으로 최근에 재직했으며, Wright Medical과 Bausch + Lomb에서 고위 마케팅 역할을 수행한 풍부한 의료 기술 산업 경험을 가지고 Treace에 합류합니다.
Treace Medical Concepts (NasdaqGS: TMCI), une entreprise de technologie médicale spécialisée dans les traitements chirurgicaux pour les hallux valgus et les déformations du médio-pied via ses procédures Lapiplasty® et Adductoplasty®, a nommé Guy Guglielmino en tant que Directeur Commercial. Dans ce nouveau rôle, Guglielmino dirigera les efforts commerciaux de l'entreprise et stimulera l'innovation, la commercialisation de produits et la croissance. Il rejoint Treace avec une vaste expérience dans l'industrie de la technologie médicale, ayant récemment été Président des Sciences de la récupération chez Enovis, avec des précédents rôles de marketing senior chez Wright Medical et Bausch + Lomb.
Treace Medical Concepts (NasdaqGS: TMCI), ein Medizintechnikunternehmen, das auf chirurgische Behandlungen von Hallux valgus und Mittelfußdeformitäten mit den Verfahren Lapiplasty® und Adductoplasty® spezialisiert ist, hat Guy Guglielmino zum Chief Commercial Officer ernannt. In dieser neuen Rolle wird Guglielmino die kommerziellen Bestrebungen des Unternehmens leiten und Innovation, Produktvermarktung und Wachstum vorantreiben. Er bringt umfangreiche Erfahrungen aus der Medizintechnikbranche mit, zuletzt als President, Recovery Sciences bei Enovis, sowie in führenden Marketingpositionen bei Wright Medical und Bausch + Lomb tätig gewesen.
- Creation of new Chief Commercial Officer position indicates strategic expansion
- Appointment brings experienced medical technology industry leadership to commercial operations
- None.
PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace’s commercial efforts and play a pivotal role in driving the Company’s next phase of rapid innovation, strategic product commercialization, and growth.
“I am thrilled to welcome Guy to the Treace team,” said John T. Treace, CEO, Founder and Board Member of Treace. “With a wealth of diverse medical technology industry experience, a demonstrated track record of strong customer engagement, leadership in innovation and product development, and a proven ability to deliver exceptional market growth, Guy is ideally suited to lead our commercial efforts.”
“I’ve always admired and respected Treace, having watched the team create and lead in entirely new market segments,” said Mr. Guglielmino. “Treace has established a new standard with an approach that deeply understands their customers’ unmet needs, resulting in groundbreaking innovations that democratize the practice of the surgical treatment of bunions and midfoot deformities. I look forward to working with John and the Treace leadership team to deliver class-leading innovation, product commercialization, and sustained market performance.”
Mr. Guglielmino joins Treace with deep medical technology industry expertise, having served in diverse senior leadership roles. Most recently, Mr. Guglielmino was President, Recovery Sciences at Enovis. Prior to that, he held senior Marketing roles at Enovis, Wright Medical, and at Bausch + Lomb. Mr. Guglielmino received his Bachelor of Science in Business & Entrepreneurship and his MBA from the Rochester Institute of Technology.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company’s expectations of innovation, product commercialization, market performance, and growth. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024, and its subsequent SEC filings. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
FAQ
Who is the new Chief Commercial Officer of Treace Medical Concepts (TMCI)?
What will be Guy Guglielmino's responsibilities at Treace Medical Concepts (TMCI)?
What is Treace Medical Concepts' (TMCI) main business focus?
